Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

High-EPA dietary supplements that can be purchased without

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
MedResCollab Member Profile
 
Followed By 2
Posts 211
Boards Moderated 0
Alias Born 01/18/19
160x600 placeholder
Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference GlobeNewswire Inc. - 8/21/2019 6:00:00 AM
Amarin (AMRN) Alert: Johnson Fistel Launches Investigation into Amarin Corporation plc; Investors Encouraged to Contact Firm PR Newswire (US) - 8/9/2019 8:53:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/9/2019 7:22:13 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 7/31/2019 6:34:48 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/31/2019 6:30:41 AM
Amarin Reports Second Quarter 2019 Financial Results and Operational Update GlobeNewswire Inc. - 7/31/2019 5:00:00 AM
Amarin Announces Underwriters’ Full Exercise of Option to Purchase Additional American Depositary Shares GlobeNewswire Inc. - 7/29/2019 5:17:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/24/2019 4:32:58 PM
Amarin to Report Second Quarter 2019 Results and Host Conference Call on July 31, 2019 GlobeNewswire Inc. - 7/24/2019 6:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/19/2019 5:01:04 PM
Amarin Prices Public Offering of American Depositary Shares GlobeNewswire Inc. - 7/18/2019 11:47:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/17/2019 4:38:44 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/17/2019 4:02:07 PM
Amarin Announces $400,000,000 Public Offering of American Depositary Shares GlobeNewswire Inc. - 7/17/2019 4:01:00 PM
Biotech Companies with Recent and Potential Near-Term Catalysts InvestorsHub NewsWire - 7/15/2019 8:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/2/2019 8:15:19 AM
Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance GlobeNewswire Inc. - 7/2/2019 6:00:00 AM
Amarin’s John Thero Awarded NJ EY Entrepreneur of The Year® 2019 Award for Life Sciences GlobeNewswire Inc. - 6/21/2019 1:39:19 PM
Amarin to Present at the 2019 BMO Prescription For Success Healthcare Conference GlobeNewswire Inc. - 6/18/2019 7:00:00 AM
CORRECTING and REPLACING -- Amarin to Present Findings Regarding Challenges of Current Treatment Options in Reducing Cardiova... GlobeNewswire Inc. - 6/7/2019 10:55:19 AM
Amarin to Present Findings Regarding Challenges of Current Treatment Options in Reducing Cardiovascular Risks for Diabetes Pa... GlobeNewswire Inc. - 6/7/2019 7:12:35 AM
Amarin to Present at the Goldman Sachs 40th Annual Global Healthcare Conference GlobeNewswire Inc. - 6/4/2019 6:00:00 AM
Pharmaceutical Industry Veteran Gwen Fisher Joins Amarin to Lead Corporate Communications GlobeNewswire Inc. - 5/30/2019 7:00:00 AM
Amarin to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire Inc. - 5/30/2019 5:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/29/2019 4:10:45 PM
MedResCollab   Tuesday, 07/09/19 09:13:31 AM
Re: bfost post# 200426
Post # of 210928 
High-EPA dietary supplements that can be purchased without a prescription (very convenient) are better than Vascepa in multiple ways. And if 4 g/d Vascepa, or the end result of taking this supplement, which is a sharp increase in serum EPA levels, can reduce the risk of ASCVD, then this advice may harm at-risk patients:

Quote:
I would encourage those of you who have family and friends who feel V is cost prohibitive to suggest they cut their costs by 25-50% by taking 2 or 3 pills/day instead of 4.

Sure RI was only 4 gms/day, but JELIS was only 1.8 gms (although in a lower risk population). Certainly 2-3 gms is better than 0 gms and we really don't know what the upper limit of efficacy is since only a 4 gm dose was used. -bfost



JELIS enrolled all of its subjects in the late 1990's (suboptimal SOC compared with today), 70% were women, and all were initially placed on very low dose statins (i.e. 5 mg/d simvastatin). 27% discontinued statin use during the study. It was also open label, with the only significant individual endpoint affected being unstable angina. And if strokes were added to the primary composite endpoint (only then making the MCE endpoint comparable with REDUCE-IT), the study would have failed with an 11.5% RRR. Strokes actually trended worse for EPA group in JELIS.

If you are hanging your hat on JELIS, and thus recommended 2 g/d, and you think REDUCE-IT results were barely at all confounded (so that nearly all of the 28% risk reduction in strokes is accurate, etc.), then you are harming those you advise, because 4 g/d may reduce strokes appreciably while 2 g/d evidently does not (per JELIS). One could carry that logic forward with other endpoints as well, as none of the individual components of the composite MCE endpoint in JELIS were significantly reduced except angina.

What would be far better advice that allows a patient to get high EPA blood serum levels (the entire goal of taking Vascepa) while also being able to actually afford the benefit? Answer: Purchasing OTC high-EPA products with third party CoAs, showing exceptional purity and accuracy of labeled quantity of EPA per dose. Also, choosing an ethyl ester EPA supplement (such as Vascepa) is subpar to other forms that have consistently shown to be better absorbed, especially when taken with a lower fat meal or with polypharmacy in evening before sleep (as many patients in a real-world setting do). For example, the very popular rTG form:



OmegaVia and Nordic Naturals exclusively produce this more modern form. In fact, these companies' products may very well be higher purity than Vascepa, as the USP-NF holds pharma companies to lower standards of TOTOX than IFOS and GOED; USP-NF allows peroxide value of up to 10 mEq/kg and p-anisidine of up to 25. Meanwhile, IFOS and GOED have these set at 5 and 20 respectively. OmegaVia (and Nordic Naturals) is well below IFOS threshold.








OmegaVia also conducts routine CoAs to ensure every batch is of very high quality:




OmegaVia is thus better absorbed than Vascepa when taken with or without food; is not dependent upon a high fat meal for absorption (as is Vascepa); and is subject to higher purity and toxicity standards than Vascepa.

Not to mention Vascepa, being a fatty acid ethyl ester, may lead to liver and other organ damage from long-term use:

https://www.jmmc-online.com/article/S0022-2828(98)90812-4/pdf

http://www.jbc.org/content/265/17/9688.full.pdf

Also see pages 55 - 66 in our citizen petition here:

http://www.jbc.org/content/265/17/9688.full.pdf

Re-esterified triglyceride forms are thus a far better choice on multiple fronts. And highly affordable:





And if one is worried about whether the dietary supplement sector can handle the demand, they seem to be doing just fine, even at the near peak of Lovaza sales:



So there you have it. Buy high EPA supplements with third-party CoAs. Probably higher purity than Vascepa, of better absorbed forms (rTG, etc.), and you can avoid ethyl ester forms that may over many years lead to organ damage. Then you can recommend the dose actually studied in REDUCE-IT, and not a dose contrived from a faulty interpretation of an older, irrelevant study (JELIS).

Regards,
-MRC Team

...
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist